Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Immuneering Corp Cl A (IMRX)

Immuneering Corp Cl A (IMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Immuneering Appoints Andrew Gengos as Chief Financial Officer GlobeNewswire - Mon Jun 15, 6:30AM CDT

- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE)...

IMRX : 4.60 (+1.32%)
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer GlobeNewswire - Thu Jun 11, 6:30AM CDT

Global pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) compared to standard GnP alone  Topline data readout, including primary...

IMRX : 4.60 (+1.32%)
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO GlobeNewswire - Mon Jun 1, 6:30AM CDT

- 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard of care chemotherapy in the pivotal MPACT study - - Only two categories of Grade 3+ treatment-related...

IMRX : 4.60 (+1.32%)
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy GlobeNewswire - Thu May 21, 4:00PM CDT

- Detailed data from 55 patients to be shared in an oral presentation at the ASCO Annual Meeting on June 1, 2026 - - Tolerability profile consistent with prior updates: only two categories of Grade...

IMRX : 4.60 (+1.32%)
Immuneering's Runway Into Twenty-Twenty-Nine: A Promise That Assumes Everything Goes According to Plan Barchart - Sun May 17, 4:00PM CDT

Barchart Research What to Expect from IMRX Earnings IMRX Generated May 15, 2026 Current Price $5.16 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Immuneering's Runway Into Twenty-Twenty-Nine:...

IMRX : 4.60 (+1.32%)
Immuneering's Runway Into Twenty-Twenty-Nine: A Promise That Assumes Everything Goes According to Plan Barchart - Sat May 16, 4:00PM CDT

Barchart Research What to Expect from IMRX Earnings IMRX Generated May 15, 2026 Current Price $5.16 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Immuneering's Runway Into Twenty-Twenty-Nine:...

IMRX : 4.60 (+1.32%)
Immuneering's Runway Into Twenty-Twenty-Nine: A Promise That Assumes Everything Goes According to Plan Barchart - Fri May 15, 4:02PM CDT

Barchart Research What to Expect from IMRX Earnings IMRX Generated May 15, 2026 Current Price $5.16 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Immuneering's Runway Into Twenty-Twenty-Nine:...

IMRX : 4.60 (+1.32%)
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates GlobeNewswire - Fri May 15, 6:35AM CDT

- New survival data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer to be presented in an oral session at 2026 ASCO Annual Meeting -  - Pivotal...

IMRX : 4.60 (+1.32%)
Can Immuneering's Pancreatic Cancer Survival Data Turn Market Skepticism Into Conviction? Barchart - Sun May 10, 4:00PM CDT

Barchart Research What to Expect from IMRX Earnings IMRX Generated May 8, 2026 Current Price $5.22 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Can Immuneering's Pancreatic Cancer...

IMRX : 4.60 (+1.32%)
Can Immuneering's Pancreatic Cancer Survival Data Turn Market Skepticism Into Conviction? Barchart - Sat May 9, 4:00PM CDT

Barchart Research What to Expect from IMRX Earnings IMRX Generated May 8, 2026 Current Price $5.22 EPS Estimate $$-0.30 Consensus Rating Strong Buy Average Move 6.69% Can Immuneering's Pancreatic Cancer...

IMRX : 4.60 (+1.32%)

Barchart Exclusives

If You Crave Dividends, This Tasty Dividend Stock Is a Buy at New 52-Week Lows Barchart - Wed Jun 24, 6:30PM CDT
Domino's Pizza stock fell to a 52-week low on June 23. With a dividend yield of 2.7% and a reasonable valuation, DPZ stock is a decent buy for income-seeking investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.